Skip to main content
Fig. 4 (abstract P385). | Journal for ImmunoTherapy of Cancer

Fig. 4 (abstract P385).

From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two

Fig. 4 (abstract P385).

Inhibition of Wnt Signaling Suppresses Gr-MDSC Recruitment in Response to anti-PD-1 Ab Therapy and Augments the Efficacy of this Checkpoint Inhibitor in a Transgenic BRAF(V600E)-PTEN-/- Melanoma Model. A. Immunohistochemistry of CXCL5 and Gr-1 in BRAF(V600E)-PTEN-/- melanoma tissue undergoing treatment with anti-PD-1 ab therapy in the absence and presence of OMP-18R5 (vantictumab, anti-Fzd7 ab) or OMP-54F28 (ipafricept, Fzd8-Fc). B. Histologic analysis of resected lung tissues to enumerate lung metastases in the transgenic BRAF(V600E)-PTEN-/- melanoma model following the indicated treatment regimens. C. Flow cytometry analysis of BRAF(V600E)-PTEN-/- melanoma tissue following the indicated treatment regimens. CD45+CD3+CD8+ T cells and CD45+CD4+FoxP3+ regulatory T cell (Treg) populations quantitated and expressed as a CD8+ T cell : Treg ratio. D. TRP2 IFNg ELISPOT analysis performed using harvested splenocytes from transgenic BRAF(V600E)-PTEN-/- mice after undergoing the indicated therapy. Representative wells shown on the right. All data is mean +/- SEM. *P<0.05

Back to article page